- HK$5.10bn
- HK$5.84bn
- CNY442.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.67 | ||
| Price to Tang. Book | 14.67 | ||
| Price to Free Cashflow | 47.69 | ||
| Price to Sales | 10.57 | ||
| EV to EBITDA | 31.68 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.29% | ||
| Return on Equity | 20.67% | ||
| Operating Margin | 36.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 350.84 | 336.77 | 442.23 | n/a | n/a | 12.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -9.29 | +59.41 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- January 1st, 1970
- Incorporated
- June 11th, 2020
- Public Since
- June 30th, 2025
- No. of Employees
- 522
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited- Shares in Issue
- 141,800,000
- Address
- No. 69, 12 Street, Qiantang District, HANGZHOU
- Web
- http://medtideinc.com
- Phone
- Auditors
- Ernst & Young
Similar to 3880
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:58 UTC, shares in Medtide are trading at HK$35.98. This share price information is delayed by 15 minutes.
Shares in Medtide last closed at HK$35.98 and the price had moved by over the past 365 days. In terms of relative price strength the Medtide share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreMedtide does not currently pay a dividend.
Medtide does not currently pay a dividend.
Medtide does not currently pay a dividend.
To buy shares in Medtide you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$35.98, shares in Medtide had a market capitalisation of HK$5.10bn.
Here are the trading details for Medtide:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3880
Based on an overall assessment of its quality, value and momentum Medtide is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medtide. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$35.98, shares in Medtide were trading +7.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medtide PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$35.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Medtide's directors